PureTech Health Plc organizacji EPS
Jaka jest wartość EPS organizacji PureTech Health Plc?
Wartość EPS organizacji PureTech Health Plc to -12.16
Jaka jest definicja EPS?
Zysk na akcję (EPS) to zysk spółki na jedną akcję. Jest dostosowywany do rozcieńczenia i obliczany w ciągu dwunastu miesięcy.
Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. Preferred stock rights have precedence over common stock. Therefore, dividends on preferred shares are subtracted before calculating the EPS. When preferred shares are cumulative, annual dividends are deducted whether or not they have been declared. Dividends in arrears are not relevant when calculating EPS. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.
EPS firm w Health Care sektor na LSE w porównaniu do PureTech Health Plc
Czym się zajmuję organizacja PureTech Health Plc?
PureTech Health plc, a clinical stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and dementia-related psychosis; a hydrogel platform technology to treat obesity and other chronic metabolic diseases; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; a immunomodulation platform to treat chronic and acute inflammatory disorders; therapies for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria; and a digital treatments to treat cognitive dysfunction associated with neurology and psychiatry conditions. It also provides hematopoietic stem cell based therapies to treat hematological malignancies; a voice-based technology platform to measure health when a person speaks; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100, an oral small molecule drug candidate to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210, a IgG1 monoclonal antibody; Glyph, a synthetic lymphatic targeting chemistry platform; milk exosome-based technology to enable the oral administration of macromolecule therapeutic payloads; and meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Roche Holding AG; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Firmy z eps podobne do PureTech Health Plc
- Wartość EPS organizacji Nxtdigital to -12.26
- Wartość EPS organizacji The Mandhana Retail Ventures to -12.25
- Wartość EPS organizacji Industrial Investment Trust to -12.23
- Wartość EPS organizacji Ramkrishna Forgings to -12.21
- Wartość EPS organizacji S Chand and to -12.20
- Wartość EPS organizacji Premier Explosives to -12.20
- Wartość EPS organizacji PureTech Health Plc to -12.16
- Wartość EPS organizacji Speciality Restaurants to -12.15
- Wartość EPS organizacji Span Divergent to -12.14
- Wartość EPS organizacji Sintex Plastics Technology to -12.07
- Wartość EPS organizacji Ashok Alco-Chem to -12.03
- Wartość EPS organizacji Netcapital to -12.00
- Wartość EPS organizacji Tata Motors to -12.00